Titre :
|
Modulating the profit motive to meet needs of the less-developed world. Commentary. (2001)
|
Auteurs :
|
Arrigo SCHIEPPATI ;
Silvio GARATTINI ;
Giuseppe REMUZZI ;
David SHARP ;
Department of Immunology and Clinical Transplantation. Azienda Ospedaliera Ospedali Riuniti. Bergamo. ITA ;
Mario Negri Institute for Pharmacological Research. Bergamo. ITA
|
Type de document :
|
Article
|
Dans :
|
Lancet (The) (vol. 358, n° 9293, 2001)
|
Pagination :
|
1570-1641 (5p.)
|
Langues:
|
Anglais
|
Mots-clés :
|
Médicament orphelin
;
Prévalence
;
Pathologie
;
Pays voie développement
;
Profit
;
Homme
;
Pharmacologie
|
Résumé :
|
[BDSP. Notice produite par INIST-CNRS gNPqR0x5. Diffusion soumise à autorisation]. The success, despite the problems, of academic/industrial collaborations over the past decade owes much to the profit motive. However, market-driven research and development has little to offer patients in the less-developed world. Some flexibility has already been demonstrated on drugs for orphan (rare or under-researched) diseases. Many diseases In less-developed countries are not rare. Academic researchers should be encouraging the establishment of funding for basic and clinical research that is directed at patients'needs in the less-developed world and that is Independent of a commercial ethos.
|